Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Livingstone

Showing results (1-10 of 181) with videos related to

Pageof 19
Sort By:
Pathologie (Heidelberg, Germany)|February 18, 2025
[Exanthematic drug eruption]Mirjana Ziemer, Elisabeth Livingstone
Dermatologie (Heidelberg, Germany)|June 8, 2023
[Fertility, teratogenicity, and contraception during therapy with BRAF/MEK inhibitors]Elisabeth Livingstone, Carola Berking
Dermatologie (Heidelberg, Germany)|May 21, 2024
[Drug-related exanthema under immunotherapy and targeted oncological therapy]Mirjana Ziemer, Elisabeth Livingstone
Dermatologie (Heidelberg, Germany)|June 23, 2023
[Fertility preservation in patients with melanoma-a huge relief for those affected]Carola Berking, Jessica C Hassel, Elisabeth Livingstone
Chinese Clinical Oncology|April 6, 2015
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their managementElisabeth Livingstone, Lisa Zimmer, Julia Vaubel, et al.
Expert Opinion on Investigational Drugs|October 15, 2010
PLX4032: does it keep its promise for metastatic melanoma treatment?Elisabeth Livingstone, Lisa Zimmer, Sarah Piel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 11, 2012
Side effects of systemic oncological therapies in dermatologyLisa Zimmer, Julia Vaubel, Elisabeth Livingstone, et al.
Onkologie|April 18, 2009
Eczematous malignant melanoma: a wolf in sheep's clothingCornelius Mensing, Elisabeth Livingstone, Thomas Schwarz, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 22, 2012
Current advances and perspectives in the treatment of advanced melanomaElisabeth Livingstone, Lisa Zimmer, Julia Vaubel, et al.
Onkologie|July 4, 2008
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical resultsFriederike Egberts, Katharina C Kahler, Elisabeth Livingstone, et al.
Pageof 19

Showing results (1-10 of 181) with videos related to

Sort By:
Pageof 19
Pathologie (Heidelberg, Germany)|February 18, 2025
[Exanthematic drug eruption]Mirjana Ziemer, Elisabeth Livingstone
Dermatologie (Heidelberg, Germany)|June 8, 2023
[Fertility, teratogenicity, and contraception during therapy with BRAF/MEK inhibitors]Elisabeth Livingstone, Carola Berking
Dermatologie (Heidelberg, Germany)|May 21, 2024
[Drug-related exanthema under immunotherapy and targeted oncological therapy]Mirjana Ziemer, Elisabeth Livingstone
Dermatologie (Heidelberg, Germany)|June 23, 2023
[Fertility preservation in patients with melanoma-a huge relief for those affected]Carola Berking, Jessica C Hassel, Elisabeth Livingstone
Chinese Clinical Oncology|April 6, 2015
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their managementElisabeth Livingstone, Lisa Zimmer, Julia Vaubel, et al.
Expert Opinion on Investigational Drugs|October 15, 2010
PLX4032: does it keep its promise for metastatic melanoma treatment?Elisabeth Livingstone, Lisa Zimmer, Sarah Piel, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|May 11, 2012
Side effects of systemic oncological therapies in dermatologyLisa Zimmer, Julia Vaubel, Elisabeth Livingstone, et al.
Onkologie|April 18, 2009
Eczematous malignant melanoma: a wolf in sheep's clothingCornelius Mensing, Elisabeth Livingstone, Thomas Schwarz, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 22, 2012
Current advances and perspectives in the treatment of advanced melanomaElisabeth Livingstone, Lisa Zimmer, Julia Vaubel, et al.
Onkologie|July 4, 2008
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical resultsFriederike Egberts, Katharina C Kahler, Elisabeth Livingstone, et al.
Pageof 19